Summit Therapeutics and partners presented updated data from the Phase 3 Harmoni trial evaluating ivonescimab combined with chemotherapy in advanced lung cancer. While early results from patients in China showed a 45% reduction in tumor progression risk, the final analysis in Western patients failed to reach statistically significant overall survival improvement, reducing enthusiasm for FDA approval. This discrepancy highlights geographic variability in drug response, a critical factor for regulatory review. Concurrently, other companies like BioNTech, Bristol Myers Squibb, and Daiichi Sankyo reported encouraging bispecific antibody and ADC data in small cell lung cancer, signaling ongoing innovation in this difficult-to-treat disease area.